Nephrolithiasis complicating treatment of diabetes insipidus.
A decrease in urine volume is considered the therapeutic goal of the treatment of central diabetes insipidus (DI) with desmopressin (dDAVP). A low urine volume is a risk factor for kidney stone formation. This is the first report of nephrolithiasis in association with DI. It is likely that successful therapy with dDAVP and the patient's own purposeful decreased fluid intake contributed to calcium oxalate stone formation. Prevention of stone recurrence requires an increase in urine volume. The patient's compliance with this recommendation led to an episode of acute hyponatremia, a well-known complication of dDAVP therapy. The challenge of the management of stones in the setting of DI requires balancing the conflicting goals of both decreasing and increasing urine volume.
Mehandru
Saurabh
S
Kidney Stone Prevention Program, New York VA Medical Center, New York, USA.
Goldfarb
David S
DS
D000328:Adult; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects*; D003919:Diabetes Insipidus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced; D007669:Kidney Calculi / Q000209:etiology*
D003894:Deamino Arginine Vasopressin